Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

SF3B1 -Mutant Myelodysplastic Syndrome with Ringed Sideroblasts (MDS-RS) at the Single-Cell Level

Rashmi Kanagal-Shamanna, MD, Vera Adema, PhD, Feiyang Ma, Bs, Andrea Santoni, PhD, Hui Yang, MD PhD, Irene Ganan-Gomez, PhD, Natthakan Thongon, PhD, Guillermo Montalban-Bravo, MD, Matteo Pellegrini, PhD, Carlos E. Bueso-Ramos, MD PhD, Guillermo Garcia-Manero, MD, Simona Colla, PhD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-141928

Published: 2020

Journal Articles

Long-Term Outcome of Low-Dose Hypomethylating Agents in Lower-Risk Myelodysplastic Syndromes: A Randomized Phase 2 Study

Koji Sasaki, MD, Elias Jabbour, MD, Guillermo Montalban Bravo, MD, Nicholas J. Short, MD, Rashmi Kanagal-Shamanna, MD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Jorge E. Cortes, MD, Farhad Ravandi, MBBS, Yesid Alvarado, MD, Kelly S. Chien, MD, Hui Yang, MD PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-139817

Published: 2020

Journal Articles

Highly-Sensitive DNA Hydroxymethylation Analysis in Myelodysplastic Syndromes (MDS)

Jia Li, PhD, Yue Wei, PhD, Minjung Lee, Hui Yang, MD PhD, Caleb Class, PhD, Stefan Siwko, Yubin Zhou, PhD, Deqiang Sun, PhD, Guillermo Garcia-Manero, MD, Yun Huang, PhD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-137733

Published: 2020

Journal Articles

Hypomethylating Agents Do Not Alter Novel Splicing Events in Myeloid Neoplasms

Hussein A Abbas, MDPhD, Feng Wang, PhD, Yue Wei, PhD, Hui Yang, MD PhD, Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Caleb Class, PhD, Faezeh Darbaniyan, PhD, Jianhua Zhang, PhD, Andy Futreal, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-140142

Published: 2020

Journal Articles

Impact of Hemoglobin Level As a Continuous Variable in Calculating Prognosis in MDS: Incorporation into LSC4 and IPSS-R

Faezeh Darbaniyan, PhD, Guillermo Montalban Bravo, MD, Yue Wei, PhD, Rashmi Kanagal-Shamanna, MD, Koji Sasaki, MD, Hui Yang, MD PhD, Kelly A. Soltysiak, PhD, Kelly S. Chien, MD, Kim-Anh Do, PhD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-140029

Published: 2020

Journal Articles

Transcriptomic Features and Deregulation of Genes Involved in Monopoiesis Influence Outcomes of Patients with Chronic Myelomonocytic Leukemia

Guillermo Montalban Bravo, MD, Faezeh Darbaniyan, PhD, Rashmi Kanagal-Shamanna, MD, Irene Ganan-Gomez, PhD, Koji Sasaki, MD, Kiran Naqvi, MD MPH, Yue Wei, PhD, Hui Yang, MD PhD, Kelly A. Soltysiak, PhD, Kelly S. Chien, MD, Carlos E. Bueso-Ramos, MD PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-137702

Published: 2020

Journal Articles

Genomic and Transcriptomic Differences of Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)

Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Faezeh Darbaniyan, PhD, Irene Ganan-Gomez, PhD, Koji Sasaki, MD, Kiran Naqvi, MD MPH, Yue Wei, PhD, Hui Yang, MD PhD, Kelly A. Soltysiak, PhD, Kelly S. Chien, MD, Carlos E. Bueso-Ramos, MD PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139983

Published: 2020

Journal Articles

Hematopoietic Architecture of MDS before and after Progression Reveals Two Biologically Distinct Disease Subtypes

Irene Gañán-Gómez, PhD, Ana Alfonso, MD, Yamini Ogoti, MS, Hui Yang, MD PhD, Guillermo Montalban-Bravo, MD, Abraham C Yu, BS, Matteo Marchesini, PhD, Carlos E Bueso-Ramos, MD PhD, Koichi Takahashi, MD, Karen Clise-Dwyer, PhD, Guillermo Garcia-Manero, MD, Simona Colla, PhD

Blood (2016) 128 (22): 4310.

https://doi.org/10.1182/blood.V128.22.4310.4310

Published: 2016

Journal Articles

Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Acute Myeloid Leukemia

Hui Yang, MD PhD, Zachary S. Bohannan, MA, Zhihong Fang, Irene Gañán-Gómez, PhD, Yue Wei, PhD, Linda J. Paradiso, DVM, MBA, Hiroyuki Iwamura, Dphil, Guillermo Garcia-Manero, MD

Blood (2016) 128 (22): 2756.

https://doi.org/10.1182/blood.V128.22.2756.2756

Published: 2016

Journal Articles

Phase 1 Results of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Blood (2016) 128 (22): 1640.

https://doi.org/10.1182/blood.V128.22.1640.1640

Published: 2016

Journal Articles

A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS)

Blood (2016) 128 (22): 344.

https://doi.org/10.1182/blood.V128.22.344.344

Published: 2016

Journal Articles

Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment

Guillermo Garcia-Manero, MD, Martin S. Tallman, MD, Giovanni Martinelli, MD, Vincent Ribrag, MD, Hui Yang, MD PhD, Arun Balakumaran, MD PhD SM, Sabine Chlosta, MD, Yayan Zhang, PhD, B. Douglas Smith, MD

Blood (2016) 128 (22): 345.

https://doi.org/10.1182/blood.V128.22.345.345

Published: 2016

Journal Articles

A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy

Guillermo Garcia-Manero, MD, Guillermo Montalban-Bravo, MD, Hui Yang, MD PhD, Yue Wei, PhD, Yesid Alvarado, MD, Courtney D. DiNardo, MD MSCE, Naval G. Daver, MD, Marina Konopleva, MD PhD, Katherine P. Hearn, BSN, RN, Robert Miller, Sarah Arbe-Barnes, Peter Mc Guirk, Tara Kearney, Brian Keogh, Hagop M. Kantarjian, MD, Mary Reilly

Blood (2016) 128 (22): 227.

https://doi.org/10.1182/blood.V128.22.227.227

Published: 2016

Journal Articles

A Phase II Clinical Trial of Azacitidine and Vorinostat for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) with Poor Performance Status, Comorbidities, Other Active Malignancies or Organ Dysfunction Not Eligible for Conventional Clinical Trials

Blood (2016) 128 (22): 1999.

https://doi.org/10.1182/blood.V128.22.1999.1999

Published: 2016

Journal Articles

Pharmacological Inhibition of Histone Demethylase JMJD3 Reduces Leukemia Cell Survival and Represses Production of the Cytokine CCL2 in MDS/AML

Yue Wei, PhD, Yu Jia, Hong Zheng, Hui Yang, MD PhD, Zachary S. Bohannan, MA, John Lee, Chong Zhao, Carlos E. Bueso-Ramos, MD, Ali N. Chamseddine, MD, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 5219.

https://doi.org/10.1182/blood.V126.23.5219.5219

Published: 2015

Journal Articles

PDE4 Differential Expression Is a Potential Prognostic Factor and a Therapeutic Target in Myelodysplastic Syndromes

Ali N. Chamseddine, MD, Yue Wei, PhD, Monica Cabrero, MD, Irene Ganan-Gomez, PhD MSc, Simona Colla, PhD, Koichi Takahashi, MD, Hui Yang, MD PhD, Marcos R Estecio, PhD, Zachary S. Bohannan, MA, Sherry Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD, Hagop M Kantarjian, MD, Elias Jabbour, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 5227.

https://doi.org/10.1182/blood.V126.23.5227.5227

Published: 2015

Journal Articles

Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Guillermo Garcia-Manero, MD, Hui Yang, MD PhD, Zhihong Fang, Courtney DiNardo, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Ricardo Delumpa, RN, Christopher Loiselle, RN, Susan Denton, RN, Whitney Smith, Hiroyuki Iwamura, PhD, Teletha Gipson, PhD, Michele Rosner, MS, Timothy Madden, PharmD, Thomas J. Myers, MD, Linda J. Paradiso, DVM, MBA

Blood (2015) 126 (23): 3800.

https://doi.org/10.1182/blood.V126.23.3800.3800

Published: 2015

Journal Articles

Focal Adhesion Kinase As a Potential Target in AML and MDS

Bing Z Carter, Steven M. Kornblau, MD, Po Yee Mak, MPhil, Hui Yang, MD PhD, Yihua Qiu, MD, Xuejie Jiang, Kevin Coombes, PhD, Nianxiang Zhang, Guillermo Garcia-Manero, MD, Michael Andreeff, MD, PhD

Blood (2015) 126 (23): 3680.

https://doi.org/10.1182/blood.V126.23.3680.3680

Published: 2015

Journal Articles

Effect of Azacytidine on the Hematopoietic Stem and Progenitor Cell Compartments of MDS Mouse Models: Unveiling the Mechanisms of Remission and Relapse

Irene Gañán-Gómez, PhD, Yamini Ogoti, Matteo Marchesini, PhD, Yue Wei, PhD, Hui Yang, MD PhD, Shan Jiang, Naran Bao, Carlos E. Bueso-Ramos, MD, Guillermo Garcia-Manero, MD, Simona Colla, PhD

Blood (2015) 126 (23): 2852.

https://doi.org/10.1182/blood.V126.23.2852.2852

Published: 2015

Journal Articles

Association Between Down-Regulation of EZH2 and Abnormal Karyotype, Response to Hypomethylation Treatment, and Patient Survival in Myelodysplastic Syndromes

Yue Wei, Monica Cabrero, MD, Yu Jia, Hong Zheng, Hui Yang, MD, PhD, Zhihong Fang, Zach Bohannan, Rui Chen, PhD, Hui Wang, PhD, Simona Colla, Xia Wang, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 3241.

https://doi.org/10.1182/blood.V124.21.3241.3241

Published: 2014

NARROW

SF3B1 -Mutant Myelodysplastic Syndrome with Ringed Sideroblasts (MDS-RS) at the Single-Cell Level

Long-Term Outcome of Low-Dose Hypomethylating Agents in Lower-Risk Myelodysplastic Syndromes: A Randomized Phase 2 Study

Highly-Sensitive DNA Hydroxymethylation Analysis in Myelodysplastic Syndromes (MDS)

Hypomethylating Agents Do Not Alter Novel Splicing Events in Myeloid Neoplasms

Impact of Hemoglobin Level As a Continuous Variable in Calculating Prognosis in MDS: Incorporation into LSC4 and IPSS-R

Transcriptomic Features and Deregulation of Genes Involved in Monopoiesis Influence Outcomes of Patients with Chronic Myelomonocytic Leukemia

Genomic and Transcriptomic Differences of Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)

Hematopoietic Architecture of MDS before and after Progression Reveals Two Biologically Distinct Disease Subtypes

Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Acute Myeloid Leukemia

Phase 1 Results of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS)

Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment

A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy

A Phase II Clinical Trial of Azacitidine and Vorinostat for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) with Poor Performance Status, Comorbidities, Other Active Malignancies or Organ Dysfunction Not Eligible for Conventional Clinical Trials

Pharmacological Inhibition of Histone Demethylase JMJD3 Reduces Leukemia Cell Survival and Represses Production of the Cytokine CCL2 in MDS/AML

PDE4 Differential Expression Is a Potential Prognostic Factor and a Therapeutic Target in Myelodysplastic Syndromes

Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Focal Adhesion Kinase As a Potential Target in AML and MDS

Effect of Azacytidine on the Hematopoietic Stem and Progenitor Cell Compartments of MDS Mouse Models: Unveiling the Mechanisms of Remission and Relapse

Association Between Down-Regulation of EZH2 and Abnormal Karyotype, Response to Hypomethylation Treatment, and Patient Survival in Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only